NeoStem Subsidiary PCT Announces Collaboration with ATMI

NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”) have announced that PCT has entered into a collaboration with ATMI, Inc.

As industry leaders, PCT and ATMI will collaborate on a non-exclusive basis enabling PCT and PCT’s affiliates to offer to their respective clients access to the Integrity® Xpansion™ technology platform from ATMI.

PCT has always been a leader in utilizing the most advanced technology and innovation to pave the path towards commercialization in the regenerative medicine industry.

The Xpansion system will provide bioreactor expansion capability to help clients of PCT and PCT’s affiliates to achieve their development goals by creating and customizing an appropriate development program to suit the needs of each client.

“PCT is pleased to be working with ATMI to offer our clients and potential clients the Xpansion system technology that we believe to be the next generation of two-dimensional technology for adherent cell culture, including stem cells,” said Robert A. Preti, Ph.D., President of PCT and Chief Scientific Officer of NeoStem.

Preti continued, “Along with our investments in Engineering and Innovation, the Xpansion system is an exciting tool that has the potential to help a valuable segment of our client base develop cellular therapeutics in a more cost effective and robust way.”

The Xpansion system is part of the ATMI LifeSciences Integrity family of single-use technologies and has been especially developed by ATMI for large-scale production of stem cells and is based on stacked plates made from the same plastic material as multiple-tray stack systems.

According to ATMI, the Xpansion platform offers many advantages over traditional 2-D cell culture technologies: it operates as a closed system, has a compact footprint, monitors and controls pH and dissolved oxygen (DO), and allows for noninvasive, real-time observation of stem cell growth at multiple locations on the top five to 10 plates.

The Xpansion system has the potential to reduce labor and capital costs and decrease chances of errors and contamination. PCT expects that the Xpansion system will be available for clients in PCT’s East and West Coast facilities.

“This collaboration is mutually beneficial to both PCT and ATMI, as we each have specialized knowledge in our respective spheres of expertise that will ultimately benefit our clients and this emerging industry,” said Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. “Our collaboration will allow us to share resources and information, and take advantage of new opportunities for business development to the benefit of our customers.”

“NeoStem and its subsidiaries continue to grow and expand the businesses through strategic partnerships, such as with ATMI. We believe these partnerships are critical to remaining at the forefront of innovation through the utilization of new technologies that will enhance efficiencies and cost-effective high quality manufacturing,” said Dr. Robin L. Smith, Chairman and CEO of NeoStem.

RELATED ARTICLES

Three medical and legal scholars discussed the implications of one couple's wrongful death suit, seeking compensation for the March 2018 loss at a fertility center of more than 4,000 frozen eggs and embryos.